CR7182A - Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales - Google Patents

Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales

Info

Publication number
CR7182A
CR7182A CR7182A CR7182A CR7182A CR 7182 A CR7182 A CR 7182A CR 7182 A CR7182 A CR 7182A CR 7182 A CR7182 A CR 7182A CR 7182 A CR7182 A CR 7182A
Authority
CR
Costa Rica
Prior art keywords
sulfonylbenzamidins
benzoilsufanamids
antitumural
agents
antitumor
Prior art date
Application number
CR7182A
Other languages
English (en)
Spanish (es)
Inventor
Hughes Corbett Thomas
Sue Grossman Cora
Karen Lobb Lynn
Lin Ho-Shen
Shih Chuan
Arthur Hipskind Phlilp
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR7182A publication Critical patent/CR7182A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • C07D213/34Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
CR7182A 2001-06-06 2003-12-05 Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales CR7182A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06

Publications (1)

Publication Number Publication Date
CR7182A true CR7182A (es) 2004-06-08

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7182A CR7182A (es) 2001-06-06 2003-12-05 Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales

Country Status (35)

Country Link
US (1) US7183320B2 (enExample)
EP (1) EP1401806B1 (enExample)
JP (1) JP4167173B2 (enExample)
KR (1) KR100880760B1 (enExample)
CN (1) CN100475787C (enExample)
AR (1) AR036079A1 (enExample)
AT (1) ATE335722T1 (enExample)
AU (1) AU2002259204B2 (enExample)
BR (1) BR0210078A (enExample)
CA (1) CA2446719A1 (enExample)
CR (1) CR7182A (enExample)
CY (1) CY1105386T1 (enExample)
CZ (1) CZ20033296A3 (enExample)
DE (1) DE60213810T2 (enExample)
DK (1) DK1401806T3 (enExample)
EA (1) EA005810B1 (enExample)
EC (1) ECSP034874A (enExample)
EG (1) EG24356A (enExample)
ES (1) ES2269688T3 (enExample)
HR (1) HRP20031000A2 (enExample)
HU (1) HUP0400114A3 (enExample)
IL (1) IL158985A0 (enExample)
MX (1) MXPA03011197A (enExample)
MY (1) MY136855A (enExample)
NO (1) NO20035366L (enExample)
NZ (1) NZ529098A (enExample)
PE (1) PE20030199A1 (enExample)
PL (1) PL367188A1 (enExample)
PT (1) PT1401806E (enExample)
SK (1) SK14642003A3 (enExample)
SV (1) SV2003001076A (enExample)
TW (1) TWI266761B (enExample)
UA (1) UA74889C2 (enExample)
WO (1) WO2002098848A1 (enExample)
ZA (1) ZA200308644B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316984T2 (de) * 2002-11-22 2008-07-17 Eli Lilly And Co., Indianapolis Benzoylsulfonamide als antitumor-mittel
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
JP5284641B2 (ja) * 2004-05-26 2013-09-11 アボット・ラボラトリーズ N−スルホニルカルボキシイミドアミドアポトーシス促進剤
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
DE602006021401D1 (de) * 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
TWI337608B (en) 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
JPWO2007123274A1 (ja) 2006-04-20 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規感受性マーカー
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
US7939532B2 (en) * 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US7879884B2 (en) 2007-05-16 2011-02-01 Hoffmann-La Roche Inc. Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE025527T2 (en) * 2009-01-19 2016-04-28 Abbvie Inc Apoptosis inducers for the treatment of cancer, immune and autoimmune diseases
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12015500297B1 (en) 2009-05-26 2023-10-20 Abbvie Ireland Unlimited Co Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
DK2550258T3 (en) * 2010-03-25 2015-12-07 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
PH12013501006A1 (en) 2010-11-23 2022-03-30 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
ES3038757T3 (en) 2015-02-13 2025-10-14 Oxford Drug Design Ltd Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
US11479532B2 (en) * 2017-06-23 2022-10-25 University Of South Florida 5-aminolevulinate synthase inhibitors and methods of use thereof
JP7164784B2 (ja) * 2017-12-29 2022-11-02 共信醫藥科技股分有限公司 ベンゼンスルホンアミド誘導体および脂質ラフトの調節方法
CN114790149B (zh) * 2021-01-26 2024-11-19 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法
WO2025031360A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
DE69628050T2 (de) 1995-10-25 2004-04-01 Senju Pharmaceutical Co., Ltd. Angiogenese Hemmer
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6380167B1 (en) * 1999-02-12 2002-04-30 Primecyte, Inc. Methods for anti-tumor therapy
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters

Also Published As

Publication number Publication date
EP1401806B1 (en) 2006-08-09
PL367188A1 (en) 2005-02-21
EA200400006A1 (ru) 2004-06-24
EP1401806A1 (en) 2004-03-31
NO20035366D0 (no) 2003-12-02
JP2004530709A (ja) 2004-10-07
ECSP034874A (es) 2004-01-28
KR100880760B1 (ko) 2009-02-02
BR0210078A (pt) 2004-06-22
ATE335722T1 (de) 2006-09-15
NZ529098A (en) 2005-08-26
HK1064360A1 (en) 2005-01-28
KR20040007656A (ko) 2004-01-24
AU2002259204B2 (en) 2008-01-17
EA005810B1 (ru) 2005-06-30
ZA200308644B (en) 2005-02-07
US20040157741A1 (en) 2004-08-12
MY136855A (en) 2008-11-28
PT1401806E (pt) 2006-11-30
HRP20031000A2 (en) 2004-04-30
DK1401806T3 (da) 2006-11-27
UA74889C2 (en) 2006-02-15
IL158985A0 (en) 2004-05-12
EG24356A (en) 2009-03-04
HUP0400114A3 (en) 2007-05-02
HUP0400114A2 (hu) 2005-04-28
CY1105386T1 (el) 2010-04-28
PE20030199A1 (es) 2003-03-12
MXPA03011197A (es) 2004-02-26
DE60213810D1 (de) 2006-09-21
JP4167173B2 (ja) 2008-10-15
WO2002098848A1 (en) 2002-12-12
SK14642003A3 (sk) 2004-12-01
TWI266761B (en) 2006-11-21
US7183320B2 (en) 2007-02-27
NO20035366L (no) 2004-02-06
CN100475787C (zh) 2009-04-08
ES2269688T3 (es) 2007-04-01
CN1514824A (zh) 2004-07-21
CZ20033296A3 (cs) 2004-04-14
SV2003001076A (es) 2003-07-29
CA2446719A1 (en) 2002-12-12
DE60213810T2 (de) 2007-02-01
AR036079A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
CR9465A (es) Compuestos mejorados farmacocineticamente
ATE433447T1 (de) Pyrimiidinverbindungen
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
ATE365740T1 (de) Substituierte pyrazolopyrimidine
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
ECSP045255A (es) Cumarinas utiles como biomarcadores
ATE375978T1 (de) Benzoylsulfonamide als antitumor-mittel
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
PA8667201A1 (es) Nuevos compuestos farmaceuticos
MXPA04003755A (es) Endoprotesis vasculares.
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
ATE387449T1 (de) Pyrazolopyrimidine
PL372769A1 (en) Cyanoguanidine prodrugs
NO20063293L (no) Farmasoytiske forbindelser
TW200605885A (en) Multicyclic lonidamine analogs
DE60304360D1 (de) N-aryl-2-oxazolidinone und deren derivate
ATE336244T1 (de) Metallorganisches antitumormittel
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
BR0214244A (pt) Uso de uma ascomicina